Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -10195.54% is 15% below its 5-year average of -8890.95%, near the high end of its 5-year range (-255711.76%–-262.77%).
85.55% above its 12-month average of -70572.67%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2025 (2025-06-30): -2056.00%.
EBITDA MARGIN
-10195.54%
EBITDA MARGIN AVG TTM
-70572.67%
EBITDA MARGIN AVG 3Y
-67623.04%
EBITDA MARGIN AVG 5Y
-8890.95%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+85.55%
CURRENT VS 3Y AVG
+84.92%
CURRENT VS 5Y AVG
-14.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inhibrx Biosciences Inc.
Market Cap
$1.42B
EBITDA Margin
-10195.54%
TTM Avg
-70572.67%
3Y Avg
-67623.04%
5Y Avg
-8890.95%
Market Cap
$1.41B
EBITDA Margin
6.32%
TTM Avg
6.34%
3Y Avg
5.49%
5Y Avg
5.03%
Market Cap
$1.44B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.38B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
Market Cap
$1.47B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
Market Cap
$1.36B
EBITDA Margin
-55.09%
TTM Avg
-213.80%
3Y Avg
-156.04%
5Y Avg
-2346.33%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibrx Biosciences Inc. (INBX) | $1.42B | -10195.54% | -70572.67% | -67623.04% | -8890.95% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 6.32% | 6.34% | 5.49% | 5.03% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 21.45% | -50.92% | -538.26% | -378.46% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.48B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 3.56% | 3.76% | 3.79% | 3.46% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | 36.35% | 36.35% | 36.35% | 36.35% |
| Omeros Corporation (OMER)vs › | $1.36B | -55.09% | -213.80% | -156.04% | -2346.33% |
| GH Research PLC (GHRS)vs › | $1.49B | N/A | N/A | N/A | N/A |
Gross Margin
-91.0%
EBITDA Margin
-10195.5%
Operating Margin
-10386.5%
Net Margin
-10773.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -2056.00% |
| 2024-12-31 | -49239.00% |
| 2024-06-30 | -160423.00% |
| 2023-12-31 | -5385.01% |
| 2023-09-30 | -38254.62% |
| 2023-06-30 | -136813.33% |
| 2023-03-31 | -255711.76% |
| 2022-12-31 | -12845.99% |
| 2022-09-30 | -10681.29% |
| 2022-06-30 | -4820.39% |
| 2022-03-31 | -3139.23% |
| 2021-12-31 | -674.08% |
| 2021-09-30 | -730.73% |
| 2021-06-30 | -2044.34% |
| 2021-03-31 | -2116.69% |
| 2020-12-31 | -606.70% |
| 2020-09-30 | -262.77% |
| 2020-06-30 | -507.44% |
| 2020-03-31 | -1990.25% |
| 2019-12-31 | -5039.70% |
| 2019-09-30 | -1577.46% |
| 2019-03-31 | -40.50% |
| 2018-12-31 | -171.13% |
| 2018-06-30 | -260.32% |
| 2018-03-31 | -349.84% |
| 2017-12-31 | -2761.92% |
